A comprehensive framework for predicting response to therapy on the basis of heterogeneity in dceMRI parameter maps is presented. A motion-correction method for dceMRI sequences is extended to incorporate uncertainties in the pharmacokinetic parameter maps using a variational Bayes framework. Simple measures of heterogeneity (with and without uncertainty) in parameter maps for colorectal cancer tumours imaged before therapy are computed, and tested for their ability to distinguish between responders and non-responders to therapy. The statistical analysis demonstrates the importance of using the spatial distribution of parameters, and their uncertainties, when computing heterogeneity measures and using them to predict response on the basis o...
The ability to predict response to neoadjuvant chemotherapy for women diagnosed with breast cancer, ...
Quantitative imaging biomarkers (QIBs) are increasingly being incorporated into early phase clinical...
AbstractThe ability to predict response to neoadjuvant chemotherapy for women diagnosed with breast ...
Cancer is one of the leading causes of premature deaths across the world today, and there is an urge...
This study aims to quantify the heterogeneity of tumour enhancement in dynamic contrast-enhanced MRI...
This study aims to quantify the heterogeneity of tumour enhancement in dynamic contrast-enhanced MRI...
Using dynamic contrast-enhanced MRI (DCE-MRI), it is possible to estimate pharmacokinetic (PK) param...
Dynamic contrast-enhanced MRI is becoming a standard tool for imaging-based trials of anti-vascular/...
Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic r...
AbstractThe purpose of this study is to investigate the ability of multivariate analysis of dynamic ...
AbstractPharmacokinetic analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) t...
Simple summary statistics of Dynamic Contrast-Enhanced MRI (DCE-MRI) parameter maps (e.g. the median...
There is rapidly increasing interest in functional imaging for the diagnosis and monitoring of disea...
This paper assesses the estimation of kinetic parameters from dynamic contrast-enhanced magnetic res...
The usage of dynamic contrast-enhanced MRI (DCE-MRI) as a clinical tool is still widely assessed. Ap...
The ability to predict response to neoadjuvant chemotherapy for women diagnosed with breast cancer, ...
Quantitative imaging biomarkers (QIBs) are increasingly being incorporated into early phase clinical...
AbstractThe ability to predict response to neoadjuvant chemotherapy for women diagnosed with breast ...
Cancer is one of the leading causes of premature deaths across the world today, and there is an urge...
This study aims to quantify the heterogeneity of tumour enhancement in dynamic contrast-enhanced MRI...
This study aims to quantify the heterogeneity of tumour enhancement in dynamic contrast-enhanced MRI...
Using dynamic contrast-enhanced MRI (DCE-MRI), it is possible to estimate pharmacokinetic (PK) param...
Dynamic contrast-enhanced MRI is becoming a standard tool for imaging-based trials of anti-vascular/...
Mechanistic modelling of dynamic MRI data predicts that tumour heterogeneity decreases therapeutic r...
AbstractThe purpose of this study is to investigate the ability of multivariate analysis of dynamic ...
AbstractPharmacokinetic analysis of dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) t...
Simple summary statistics of Dynamic Contrast-Enhanced MRI (DCE-MRI) parameter maps (e.g. the median...
There is rapidly increasing interest in functional imaging for the diagnosis and monitoring of disea...
This paper assesses the estimation of kinetic parameters from dynamic contrast-enhanced magnetic res...
The usage of dynamic contrast-enhanced MRI (DCE-MRI) as a clinical tool is still widely assessed. Ap...
The ability to predict response to neoadjuvant chemotherapy for women diagnosed with breast cancer, ...
Quantitative imaging biomarkers (QIBs) are increasingly being incorporated into early phase clinical...
AbstractThe ability to predict response to neoadjuvant chemotherapy for women diagnosed with breast ...